Aptevo Therapeutics Inc. SEC filings APVO
Aptevo Therapeutics Inc. has 740 filings in SEC EDGAR's recent list, going back to Apr 15, 2016. Its latest annual report, Form ARS, was filed on Jul 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 2, 2026 | — |
| CORRESP | Letter to the SEC | Aug 31, 2026 | — |
| UPLOAD | Letter from the SEC | Aug 27, 2026 | — |
| D | Filing | Aug 26, 2026 | — |
| EFFECT | Filing | Jan 30, 2026 | — |
| CORRESP | Letter to the SEC | Jan 29, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 29, 2026 | — |
| EFFECT | Filing | Nov 25, 2025 | — |
| CORRESP | Letter to the SEC | Nov 24, 2025 | — |
| EFFECT | Filing | Aug 1, 2025 | — |
| CORRESP | Letter to the SEC | Jul 31, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 30, 2025 | — |
| EFFECT | Filing | Jun 18, 2025 | — |
| CORRESP | Letter to the SEC | Jun 16, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 4, 2025 | — |
| DRS | Filing | May 30, 2025 | — |
| EFFECT | Filing | May 22, 2025 | — |
| CORRESP | Letter to the SEC | May 21, 2025 | — |
| UPLOAD | Letter from the SEC | May 20, 2025 | — |
| RW | Filing | May 13, 2025 | — |
| RW | Filing | May 13, 2025 | — |
| D | Filing | Apr 18, 2025 | — |
| EFFECT | Filing | Feb 26, 2025 | — |
| CORRESP | Letter to the SEC | Feb 24, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 21, 2025 | — |
| EFFECT | Filing | Jan 2, 2025 | — |
| CORRESP | Letter to the SEC | Jan 2, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 30, 2024 | — |
| EFFECT | Filing | Sep 16, 2024 | — |
| CORRESP | Letter to the SEC | Sep 11, 2024 | — |
| CORRESP | Letter to the SEC | Sep 11, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 6, 2024 | — |
| EFFECT | Filing | Jun 28, 2024 | — |
| CORRESP | Letter to the SEC | Jun 25, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 20, 2024 | — |
| EFFECT | Filing | Apr 10, 2024 | — |
| CORRESP | Letter to the SEC | Apr 8, 2024 | — |
| CORRESP | Letter to the SEC | Apr 8, 2024 | — |
| CORRESP | Letter to the SEC | Mar 29, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 29, 2024 | — |
| DEFR14A | Filing | Jan 30, 2024 | — |
| DEFR14A | Filing | Jan 16, 2024 | — |
| EFFECT | Filing | Nov 30, 2023 | — |
| CORRESP | Letter to the SEC | Nov 29, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 29, 2023 | — |
| EFFECT | Filing | Aug 1, 2023 | — |
| CORRESP | Letter to the SEC | Aug 1, 2023 | — |
| CORRESP | Letter to the SEC | Aug 1, 2023 | — |
| CORRESP | Letter to the SEC | Jul 28, 2023 | — |
| CORRESP | Letter to the SEC | Jul 28, 2023 | — |
| CORRESP | Letter to the SEC | Jul 26, 2023 | — |
| CORRESP | Letter to the SEC | Jul 26, 2023 | — |
| CORRESP | Letter to the SEC | Jul 21, 2023 | — |
| CORRESP | Letter to the SEC | Jul 21, 2023 | — |
| CORRESP | Letter to the SEC | Jul 14, 2023 | — |
| CORRESP | Letter to the SEC | Jul 14, 2023 | — |
| UPLOAD | Letter from the SEC | Jul 6, 2023 | — |
| EFFECT | Filing | Aug 19, 2021 | — |
| CORRESP | Letter to the SEC | Aug 17, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 17, 2021 | — |
| DEFC14A | Filing | May 11, 2021 | — |
| CORRESP | Letter to the SEC | May 5, 2021 | — |
| UPLOAD | Letter from the SEC | May 4, 2021 | — |
| PREC14A | Filing | Apr 28, 2021 | — |
| DFAN14A | Filing | Feb 9, 2021 | — |
| EFFECT | Filing | Dec 18, 2020 | — |
| CORRESP | Letter to the SEC | Dec 17, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 17, 2020 | — |
| 8-A12B | Form 8-a12b | Nov 9, 2020 | — |
| SC TO-I/A | Filing | Jul 29, 2020 | — |
| SC TO-I/A | Filing | Jul 13, 2020 | — |
| SC TO-I | Filing | Jun 29, 2020 | — |
| DEFR14A | Filing | Apr 26, 2019 | — |
| EFFECT | Filing | Feb 13, 2019 | — |
| CORRESP | Letter to the SEC | Feb 11, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2018 | — |
| CORRESP | Letter to the SEC | Jul 27, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2018 | — |
| EFFECT | Filing | Dec 15, 2017 | — |
| CORRESP | Letter to the SEC | Dec 14, 2017 | — |
| CORRESP | Letter to the SEC | Dec 6, 2017 | — |
| CT ORDER | Filing | Nov 30, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 22, 2017 | — |
| CT ORDER | Filing | Jul 21, 2016 | — |
| CERTNAS | Auto-generated paper document | Jul 14, 2016 | — |
| CORRESP | Letter to the SEC | Jul 13, 2016 | — |
| 10-12B/A | Filing | Jul 13, 2016 | — |
| CORRESP | Letter to the SEC | Jul 7, 2016 | — |
| 10-12B/A | Filing | Jul 7, 2016 | — |
| UPLOAD | Letter from the SEC | Jul 5, 2016 | — |
| 10-12B/A | Form 10-12b/a | Jun 29, 2016 | — |
| CORRESP | Letter to the SEC | Jun 28, 2016 | — |
| UPLOAD | Letter from the SEC | Jun 16, 2016 | — |
| CORRESP | Letter to the SEC | May 31, 2016 | — |
| 10-12B/A | Form 10-12b/a | May 31, 2016 | — |
| UPLOAD | Letter from the SEC | May 13, 2016 | — |
| 10-12B | Filing | Apr 15, 2016 | — |
| CORRESP | Letter to the SEC | Apr 15, 2016 | — |
Showing 99 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APVO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Seattle, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1671584
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.